If you’re looking for a basing pattern that has recently bent itself around toward a bullish breakout, then you would probably be happy to stumble across the Kali Inc (OTCMKTS:KALY) chart. Shares of the stock have been tracing sideways with very definite support at the one penny level for most of 2019. That action was followed up last week by a clear breakout above its multi-month range highs. To further flesh out the story, the company just announced plans to reveal a fourth research and development initiative for a treatment of a heath issue with a cannabis extract derived from the company’s patented cannabis extraction process.
According to the release, “the company currently has ongoing cannabis extract research and development targeting four specific health issues, COPD, Type 2 Diabetes, Cancer Pain Management and one additional health issue KALY plans to announce next week leading up to an online presentation with more detail on each of the treatment developments later this month. The market for Type 2 Diabetes is expected to be a $64 billion market by 2026. The market for COPD treatment is anticipated to reach $14 billion by 2025. The overall pain management treatment market is anticipated to reach $83 billion by 2024. Beyond the four specific cannabis therapies currently in various stages of research and development, KALY has a number of additional target therapies in its research pipeline.”
Kali Inc (OTCMKTS:KALY) trumpets itself as a developer and owner of a patented cannabis extraction process – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”
This came about on November 15, 2018, with the acquisition of NCM Biotech.
With the patented intellectual property (IP), to include the existing and ongoing research and development acquired from NCM Biotech, Kali now focuses on the development of pharmaceuticals to treat various illnesses, diseases and chronic pain as a symptom of various diagnoses. Kali also concentrates on the development of health and wellness therapies.
NCM Biotech (acquired by Kali-Extracts) in collaboration with Beech Tree Labs, Inc. (BTL) of Providence, Rhode Island, conducted a series of in vitro genomic experiments to evaluate the potential of cannabis extracts derived from KALY’s patented extraction process in the treatment of respiratory diseases. The experiments were designed to evaluate pure cannabis extracts and cannabis extracts in combination with other therapies in the treatment of chronic obstructive pulmonary disease (COPD) and Asthma. There are a significant number of genes associated with COPD and Asthma. The experiments evaluated the ability of various formulations to change Asthma or COPD associated gene expressions in human small airway epithelial cells. A cannabis extract alone demonstrated remarkable activity in gene arrays by up- or down-regulating individual genes by as much as 200-fold. Genes appearing especially sensitive to the introduction of cannabis extract were associated with inflammation, healing and cancer inhibition. Results from this series of experiments provided a baseline for comparison with data from subsequent studies.
In addition, KALY has entered into a joint venture agreement named US Cannabis Health with Puration, Inc. (USOTC: PURA), and Nouveau Pharmaceuticals, Inc. (USOTC: NOUV) to combine their respective resources for the specific purpose of developing partnerships with major pharmaceutical companies to produce medical cannabis therapies.
Find out when $KALY reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, KALY just announced plans to reveal a fourth research and development initiative for the treatment of a health issue with a cannabis extract derived from the company’s patented cannabis extraction process. Recent action has seen 67% during the past week in terms of shareholder gains in the listing.
What’s more, the stock has seen a growing influx of trading interest, with the stock’s recent average trading volume running 170% above its longer-run average levels. Traders should note this as important with the stock trading on a float that is very limited at just shares.
According to the release, “in addition to its pharmaceutical developments, KALY is generating revenue from its patented cannabis extraction process delivering proprietary extracts for infusion into non-pharmaceutical commercial products. KALY announced last week finalizing its all-new 25 mg CBD Extract formulation for beverage infusion. KALY’s patented extraction process already produces a 10 mg CBD formulation for Puration, Inc.’s (USOTC: PURA) leading EVERx CBD Sports Water. KALY has also recently announced plans to provide commercial extraction for Nouveau, Inc. (USOTC: NOUV) in conjunction with NOUV’s recently announced 100-acre hemp farm.”
Earning a current market cap value of $23.33M, KALY has virtually no cash on the books, which compares with about $185K in total current liabilities. KALY is pulling in trailing 12-month revenues of $119K. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 205.1%. This is an exciting story, and we look forward to a follow-up chapter as events transpire. Sign-up for continuing coverage on shares of $KALY stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $KALY, either long or short, and we have not been compensated for this article.